Mechanism of Action
GLP-1 Receptor Agonism
Last updated
The compound activates the receptor for glucagon-like peptide-1, a hormone the gut releases after eating. Those receptors sit on pancreatic beta cells, in the brain, and in the stomach and blood vessels, so a single receptor action produces several separate effects: insulin release, slowed stomach emptying, and reduced appetite signalling. The insulin effect is glucose-dependent, meaning it is largely switched on by a rising blood sugar rather than acting regardless of it.
Why it matters here
This is the most common mechanism on the site, and each downstream effect carries its own rung rather than inheriting the receptor's. The rubric at /evidence/rubric is what keeps them separate.
What it is not
GLP-1 receptor agonist names a receptor action, not a class of interchangeable products, and it says nothing about potency, half-life or dosing interval. The alias glp-1 agonist resolves both here and to our GLP-1 Agonists category, so check whether a field holds a mechanism or a shelf. GLP-1 is also not GLP-2: same precursor protein, different receptor, different tissue.
Also called
- glp-1 agonist
- glp1 receptor agonism
- glucagon-like peptide-1 receptor agonism
- glp-1 receptor
- incretin agonism
- glp1 agonist
GLP-1 is glucagon-like peptide-1, named for its resemblance to glucagon, though its effect on blood sugar is the opposite. Incretin agonism is a broader label covering both this and GIP Receptor Agonism.